Foundations - Gene-ius Prescribing
- Pharmacogenomics (PGx): The science studying how genetic variations influence an individual's response to medications. It bridges pharmacology and genomics.
- Core Goals:
- Enhance drug efficacy (↑).
- Reduce adverse drug reactions (ADRs ↓).
- Significance: Crucial for personalized medicine, guiding drug choice and dosing based on unique genetic profiles for safer, more effective treatments.
⭐ Pharmacogenomics aims to tailor drug therapy at the individual level based on genetic makeup.
Star Players - Medication Matchmakers
| Gene | Drug(s) | Key Impact (Polymorphism) | Clinical Action (NEET PG Focus) | Notes (📌 Mnemonic / ⭐ Fact / 🇮🇳 India) |
|---|---|---|---|---|
| CYP2C19 | Clopidogrel | Poor Metabolizers (PM): ↓ active drug, ↑ MACE risk | Consider alternative (prasugrel, ticagrelor). | 📌 Clopidogrel Cries Poorly. 🇮🇳 High LoF allele prevalence in Indians. |
| CYP2D6 | Codeine, Tramadol | PM: ↓ analgesia; Ultra-Rapid Metabolizers (UM): ↑ toxicity | Codeine: Avoid in PM/UM. Tramadol: Adjust/avoid. | |
| TPMT, NUDT15 | Thiopurines (Azathioprine, 6-MP) | ↓ enzyme activity: ↑ myelosuppression risk | Dose reduction or alternative. NUDT15 variants common in Asians. | |
| HLA-B*5701 | Abacavir | Positive: ↑ severe hypersensitivity reaction (HSR) risk | Mandatory screening. Contraindicated if positive. | ⭐ > HLA-B*5701 screening mandatory before abacavir for HSR prevention. |
| VKORC1, CYP2C9 | Warfarin | Variants alter sensitivity & metabolism | Genotype-guided dosing (consider for initiation). | |
| SLCO1B1 | Statins (Simvastatin) | c.521T>C: ↓ uptake, ↑ myopathy risk with simvastatin >20mg | ↓ simvastatin dose / alternative statin. |
Clinical Integration - Lab to Bedside
Integrating pharmacogenomics (PGx) from lab to clinic personalizes medicine via a structured process.
- PGx Testing Process:
- Pre-test counseling (benefits, limitations).
- Sample collection (blood/saliva).
- Genotyping/Sequencing identifies variants.
- Interpretation: Relates genotype to phenotype, guiding drug choice/dose.
- CPIC Guidelines: Essential for translating genetic data into actionable, evidence-based clinical recommendations for gene-drug pairs.
- Clinical Decision Support Systems (CDSS):
- Integrate PGx data into EHR workflow, alerting prescribers.
- Reactive testing: Drug-specific, ordered when needed.
- Preemptive testing: Panel-based, results available for future decisions.
⭐ CPIC guidelines provide peer-reviewed, evidence-based, and actionable recommendations for gene-drug pairs.
Hurdles & Horizons - Gene Challenges, Future Wins
- Key Barriers:
- Cost of PGx testing.
- Limited clinician education & awareness.
- EMR integration challenges.
- Ethical, Legal, Social Implications (ELSI) like data privacy.
- Slow turnaround time for results.
- Indian Context Challenges:
- Significant genetic diversity.
- Infrastructural & affordability constraints.
- Dearth of India-specific guidelines & population data.
⭐ Lack of clinician education and standardized guidelines are major barriers to widespread PGx implementation.
- Future Horizons:
- Artificial Intelligence (AI) in PGx.
- Polygenic risk scores for complex traits.
- Broader preemptive genetic testing.
High‑Yield Points - ⚡ Biggest Takeaways
- CPIC guidelines provide actionable recommendations for gene-drug interactions.
- CYP2D6 variants impact metabolism of codeine, tamoxifen, and many antidepressants.
- CYP2C19 loss-of-function alleles reduce clopidogrel efficacy; consider alternatives.
- Mandatory HLA-B*5701 testing before abacavir prevents life-threatening hypersensitivity.
- HLA-B*1502 screening (especially in Asian populations) is crucial before carbamazepine to avoid SJS/TEN.
- TPMT and NUDT15 genotyping is essential for thiopurine (azathioprine, 6-MP) dosing to prevent severe myelosuppression.
- Warfarin dosing is significantly influenced by CYP2C9 and VKORC1 polymorphisms.
Unlock the full lesson and continue reading
Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more
